Literature DB >> 54923

A molecular concept of the properdin pathway.

R G Medicus, R D Schreiber, O Götze, H J Müller-Eberhard.   

Abstract

The sequential events of the properdin system were analyzed. Properdin-depleted serum allows the formation of a Factor B- and D-dependent C3 convertase. This enzyme, called the properdin-receptor-forming enzyme, was shown to utilize a novel serum component, the initiating factor. The protein is a beta-globulin in precursor form and is distinct from immunoglobulins. The function of the enzyme is to deposit C3b on the surface of activator particles. Apparently doublets of C3b are required for the formation of the properdin-activating principle. It consists of a complex containing surface-bound C3b and activated Factor B. properdin precursor is activated by binding to this complex without detectable change in molecular weight. The transition of properdin precursor to activated properdin is probably caused by a conformational change. The complex, consisting of bound C3b, properdin, and activated Factor B, represents the enzyme that acts on C5, thereby initiating self-assembly of the membrane attack system. Native C3 is not needed for the function of the enzyme. It is disassembled by soluble C3 or C3b and its formation is under the control of the properdin-receptor-destroying enzyme, which may be identical with the C3b inactivator.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 54923      PMCID: PMC335961          DOI: 10.1073/pnas.73.2.612

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

2.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

3.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

4.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

5.  Third component of complement (C3): structural properties in relation to functions.

Authors:  V A Bokisch; M P Dierich; H J Mūller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

6.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

7.  The role of properdin in the alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

8.  A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.

Authors:  E H Vallota; O Götze; H L Spiegelberg; J Forristal; C D West; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

9.  The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex.

Authors:  W P Kolb; H J Muller-Eberhard
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  31 in total

1.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

2.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

3.  Changes in humoral components of host defense following burn trauma.

Authors:  A B Bjornson; W A Altemeier; H S Bjornson
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

4.  Structural basis for therapeutic inhibition of complement C5.

Authors:  Matthijs M Jore; Steven Johnson; Devon Sheppard; Natalie M Barber; Yang I Li; Miles A Nunn; Hans Elmlund; Susan M Lea
Journal:  Nat Struct Mol Biol       Date:  2016-03-28       Impact factor: 15.369

5.  Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins).

Authors:  A P Osmand; B Friedenson; H Gewurz; R H Painter; T Hofmann; E Shelton
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

6.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

Authors:  R D Schreiber; M K Pangburn; P H Lesavre; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

7.  Immune reactants in cryoproteins. Relationship to complement activation.

Authors:  M R Wilson; C M Arroyave; L Miles; E M Tan
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

8.  Solid phase activation of alternative pathway of complement by beta-1,3-glucans and its possible role for tumour regressing activity.

Authors:  J Hamuro; U Hadding; D Bitter-Suermann
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

9.  Contribution of immunoglobulins M and G, complement, and properdin to the intracellular killing of Escherichia coli by polymorphonuclear leukocytes.

Authors:  J Menzel; H Jungfer; D Gemsa
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

10.  Effects of antibiotic resistance plasmids on the bactericidal activity of normal rabbit serum.

Authors:  A M Reynard; M E Beck; R K Cunningham
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.